DCTH | Delcath Systems, Inc. Company profile
Company profileDelcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product ? HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) ? is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.. MORE About the CompanyDelcath Systems, Inc. Delcath Systems, Inc. is a publicly-traded specialty pharmaceutical and medical device company that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body.
Address1633 Broadway Key Persons / Board of Directors
| NotesJump to (Finance sites)         ResearchInvestor pagedelcath.comIf you are looking for News & events, Press Release, they are available on their Investors Relationssite. Homepage: delcath.comTheir Official Profiles  Other stocks            Support this projectIf you want to help pay for server cost or for improving this tool. You can send it via Paypal. Social MediaRecommended Books Buy on Amazon While many books explain the how of bitcoin, The Internet of Money delves into the why of bitcoin. Acclaimed information-security expert and author of Mastering Bitcoin, Andreas M. Antonopoulos examines and contextualizes the significance of bitcoin through a series of essays spanning the exhilarating maturation of this technology. |